Journal
JOURNAL OF HEPATOLOGY
Volume 67, Issue 6, Pages 1324-1331Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2017.07.005
Keywords
Acetaminophen; Hepatotoxicity; APAP
Categories
Funding
- NIDDK [U-01 DK58369]
- Southwestern Medical Foundation, Dallas TX, USA
Ask authors/readers for more resources
Acetaminophen (APAP) is the most commonly used drug for the treatment of pain and fever around the world. At the same time, APAP can cause dose-related hepatocellular necrosis, responsible for nearly 500 deaths annually in the United States (US) alone, as well as 100,000 calls to US Poison Control Centers, 50,000 emergency room visits and 10,000 hospitalisations per year. As an over-the-counter and prescription product (with opioids), APAP toxicity dwarfs all other prescription drugs as a cause of acute liver failure in the US and Europe, but it is not regulated in any significant way. In this review the ongoing controversy surrounding the proper role for this ubiquitous pain reliever: its history, pathogenesis, clinical challenges in recognition and management, and current regulatory status are highlighted. A new solution to a 50-year-old problem is proposed. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available